collection
MENU ▼
Read by QxMD icon Read
search

Nephropathy treatment

shared collection
122 papers 1000+ followers Newer and well established treatments to slow progression of nephropathy
By Faye Kehler Family Physician and GP Anesthetist since 1987 interested in all aspects of Medicine
https://www.readbyqxmd.com/read/27670788/acute-kidney-injury-2016-diagnosis-and-diagnostic-workup
#1
Marlies Ostermann, Michael Joannidis
Acute kidney injury (AKI) is common and is associated with serious short- and long-term complications. Early diagnosis and identification of the underlying aetiology are essential to guide management. In this review, we outline the current definition of AKI and the potential pitfalls, and summarise the existing and future tools to investigate AKI in critically ill patients.
September 27, 2016: Critical Care: the Official Journal of the Critical Care Forum
https://www.readbyqxmd.com/read/27496911/recent-developments-in-the-detection-and-management-of-acute-kidney-injury
#2
REVIEW
James McCaffrey, Ajaya Kumar Dhakal, David V Milford, Nicholas J A Webb, Rachel Lennon
Acute kidney injury (AKI) is a common condition in children admitted to hospital and existing serum and urine biomarkers are insensitive. There have been significant developments in stratifying the risk of AKI in children and also in the identification of new AKI biomarkers. Risk stratification coupled with a panel of AKI biomarkers will improve future detection of AKI, however, paediatric validation studies in mixed patient cohorts are required. The principles of effective management rely on treating the underlying cause and preventing secondary AKI by the appropriate use of fluids and medication...
August 5, 2016: Archives of Disease in Childhood
https://www.readbyqxmd.com/read/27152262/stop-chronic-kidney-disease-progression-time-is-approaching
#3
REVIEW
Usama Abdel Azim Sharaf El Din, Mona Mansour Salem, Dina Ossama Abdulazim
Progression of chronic kidney disease (CKD) is inevitable. However, the last decade has witnessed tremendous achievements in this field. Today we are optimistic; the dream of withholding this progression is about to be realistic. The recent discoveries in the field of CKD management involved most of the individual diseases leading the patients to end-stage renal disease. Most of these advances involved patients suffering diabetic kidney disease, chronic glomerulonephritis, polycystic kidney disease, renal amyloidosis and chronic tubulointerstitial disease...
May 6, 2016: World Journal of Nephrology
https://www.readbyqxmd.com/read/27099136/evidence-based-clinical-practice-guidelines-for-nephrotic-syndrome-2014
#4
REVIEW
Shinichi Nishi, Yoshifumi Ubara, Yasunori Utsunomiya, Koichi Okada, Yoko Obata, Hiroyasu Kai, Hideyasu Kiyomoto, Shin Goto, Tsuneo Konta, Yoshie Sasatomi, Yoshinobu Sato, Tomoya Nishino, Kazuhiko Tsuruya, Kengo Furuichi, Junichi Hoshino, Yasuhiro Watanabe, Kenjiro Kimura, Seiichi Matsuo
No abstract text is available yet for this article.
June 2016: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/26880451/treatment-of-hyperkalemia-something-old-something-new
#5
REVIEW
Richard H Sterns, Marvin Grieff, Paul L Bernstein
Treatment options for hyperkalemia have not changed much since the introduction of the cation exchange resin, sodium polystyrene sulfonate (Kayexalate, Covis Pharmaceuticals, Cary, NC), over 50 years ago. Although clinicians of that era did not have ready access to hemodialysis or loop diuretics, the other tools that we use today-calcium, insulin, and bicarbonate-were well known to them. Currently recommended insulin regimens provide too little insulin to achieve blood levels with a maximal kalemic effect and too little glucose to avoid hypoglycemia...
March 2016: Kidney International
https://www.readbyqxmd.com/read/26690796/prevention-and-treatment-of-sepsis-induced-acute-kidney-injury-an-update
#6
Patrick M Honore, Rita Jacobs, Inne Hendrickx, Sean M Bagshaw, Olivier Joannes-Boyau, Willem Boer, Elisabeth De Waele, Viola Van Gorp, Herbert D Spapen
Sepsis-induced acute kidney injury (SAKI) remains an important challenge in critical care medicine. We reviewed current available evidence on prevention and treatment of SAKI with focus on some recent advances and developments. Prevention of SAKI starts with early and ample fluid resuscitation preferentially with crystalloid solutions. Balanced crystalloids have no proven superior benefit. Renal function can be evaluated by measuring lactate clearance rate, renal Doppler, or central venous oxygenation monitoring...
December 2015: Annals of Intensive Care
https://www.readbyqxmd.com/read/26233732/efficacy-of-febuxostat-for-slowing-the-gfr-decline-in-patients-with-ckd-and-asymptomatic-hyperuricemia-a-6-month-double-blind-randomized-placebo-controlled-trial
#7
RANDOMIZED CONTROLLED TRIAL
Dipankar Sircar, Soumya Chatterjee, Rajesh Waikhom, Vishal Golay, Arpita Raychaudhury, Suparna Chatterjee, Rajendra Pandey
BACKGROUND: Hyperuricemia is a putative risk factor for the progression of chronic kidney disease (CKD). We hypothesized that control of asymptomatic hyperuricemia may slow disease progression in CKD. STUDY DESIGN: This was a single-center, double-blind, randomized, parallel-group, placebo-controlled study. SETTING & PARTICIPANTS: Eligible participants were adults from Eastern India aged 18 to 65 years with CKD stages 3 and 4, with asymptomatic hyperuricemia...
December 2015: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/26752337/proton-pump-inhibitor-use-and-the-risk-of-chronic-kidney-disease
#8
MULTICENTER STUDY
Benjamin Lazarus, Yuan Chen, Francis P Wilson, Yingying Sang, Alex R Chang, Josef Coresh, Morgan E Grams
IMPORTANCE: Proton pump inhibitors (PPIs) are among the most commonly used drugs worldwide and have been linked to acute interstitial nephritis. Less is known about the association between PPI use and chronic kidney disease (CKD). OBJECTIVE: To quantify the association between PPI use and incident CKD in a population-based cohort. DESIGN, SETTING, AND PARTICIPANTS: In total, 10,482 participants in the Atherosclerosis Risk in Communities study with an estimated glomerular filtration rate of at least 60 mL/min/1...
February 2016: JAMA Internal Medicine
https://www.readbyqxmd.com/read/26759046/targeting-serum-calcium-in-chronic-kidney-disease-and-end-stage-renal-disease-is-normal-too-high
#9
W Charles O'Neill
Hypocalcemia is common in advanced chronic kidney disease (CKD) and end-stage renal disease (ESRD), and it is standard practice to correct this back to the normal range, presumably to prevent symptomatic hypocalcemia and help control hyperparathyroidism. However, there are few studies to support this approach, and recent data suggest that this promotes vascular calcification and adynamic bone disease. Whether setting a lower target will improve outcomes has not been tested, but existing data suggest that this may have minimal risks and substantial potential benefits and should be explored...
January 2016: Kidney International
https://www.readbyqxmd.com/read/26759049/the-mest-score-provides-earlier-risk-prediction-in-lga-nephropathy
#10
Sean J Barbour, Gabriela Espino-Hernandez, Heather N Reich, Rosanna Coppo, Ian S D Roberts, John Feehally, Andrew M Herzenberg, Daniel C Cattran
The Oxford Classification of IgA nephropathy (IgAN) includes the following four histologic components: mesangial (M) and endocapillary (E) hypercellularity, segmental sclerosis (S) and interstitial fibrosis/tubular atrophy (T). These combine to form the MEST score and are independently associated with renal outcome. Current prediction and risk stratification in IgAN requires clinical data over 2 years of follow-up. Using modern prediction tools, we examined whether combining MEST with cross-sectional clinical data at biopsy provides earlier risk prediction in IgAN than current best methods that use 2 years of follow-up data...
January 2016: Kidney International
https://www.readbyqxmd.com/read/25742686/risk-of-dementia-in-peritoneal-dialysis-patients-compared-with-hemodialysis-patients
#11
COMPARATIVE STUDY
Dawn F Wolfgram, Aniko Szabo, Anne M Murray, Jeff Whittle
BACKGROUND: Compared with similarly aged controls, patients with end-stage renal disease (ESRD) have a higher prevalence of cognitive impairment and more rapid cognitive decline, which is not explained by traditional risk factors alone. Since previous small studies suggest an association of cognitive impairment with dialysis modality, we compared incident dementia among patients initiating hemodialysis (HD) vs peritoneal dialysis (PD) in a large national cohort. METHODS: This is a retrospective cohort study of incident dialysis patients in the United States from 2006 to 2008 with no diagnosis of dementia prior to beginning dialysis...
March 2015: Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
https://www.readbyqxmd.com/read/25011387/interleukin-6-in-renal-disease-and-therapy
#12
REVIEW
Simon A Jones, Donald J Fraser, Ceri A Fielding, Gareth W Jones
Interleukin (IL)-6 has become a major target for clinical intervention in various autoimmune conditions. Here, drugs including the humanized anti-IL-6 receptor (IL-6R) antibody tocilizumab emphasize the clinical importance of IL-6 in driving disease and poor patient outcomes. During the course of this review, we will outline the biology surrounding IL-6 and discuss the impact of IL-6 in renal disease and the clinical complications associated with renal replacement therapies and transplantation. We will also consider the merit of IL-6 measurement as a prognostic indicator and provide a clinical perspective on IL-6-blocking therapies in renal disease...
April 2015: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/24829463/chronic-kidney-disease-rather-than-illness-severity-predicts-medium-to-long-term-mortality-and-renal-outcome-after-acute-kidney-injury
#13
Mark Findlay, Ken Donaldson, Sue Robertson, Alison Almond, Robert Flynn, Chris Isles
BACKGROUND: Acute kidney injury (AKI) requiring renal replacement therapy (RRT) continues to be associated with a hospital mortality of ∼50%. Longer-term outcomes have been less well studied. We sought to determine the influence of ventilation and of underlying chronic kidney disease (CKD) on medium and longterm mortality and renal outcomes. METHODS: All patients requiring RRT for AKI in south west Scotland between 1 January 1994 and 31 December 2005 were followed prospectively...
April 2015: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/24589721/focal-segmental-glomerulosclerosis-towards-a-better-understanding-for-the-practicing-nephrologist
#14
REVIEW
Sanjeev Sethi, Richard J Glassock, Fernando C Fervenza
Focal and segmental glomerulosclerosis (FSGS) is a common histopathological lesion that can represent a primary podocytopathy, or occur as an adaptive phenomenon consequent to nephron mass reduction, a scar from a healing vasculitic lesion, direct drug toxicity or viral infection among other secondary causes. Thus, the presence of an FSGS lesion in a renal biopsy does not confer a disease diagnosis, but rather represents the beginning of an exploratory process, hopefully leading ultimately to identification of a specific etiology and its appropriate treatment...
March 2015: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/25586405/microscopic-nephrocalcinosis-in-chronic-kidney-disease-patients
#15
Pieter Evenepoel, Kristien Daenen, Bert Bammens, Kathleen Claes, Björn Meijers, Maarten Naesens, Ben Sprangers, Dirk Kuypers, Eveline Lerut
BACKGROUND: Experimental data indicate that microscopic calcium phosphate deposition in the kidney (nephrocalcinosis) may accelerate progression of chronic kidney disease (CKD). Data on the prevalence, risk factors and implications of nephrocalcinosis in CKD patients are scarce. A mineral metabolism disorder could play an important pathogenetic role, as suggested by recent protocol biopsy findings in incident renal transplant recipients. METHODS: Kidney biopsy cylinders of CKD patients, collected between January 1989 and December 2007, were screened for the presence of nephrocalcinosis...
May 2015: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/24323134/lipid-management-in-chronic-kidney-disease-synopsis-of-the-kidney-disease-improving-global-outcomes-2013-clinical-practice-guideline
#16
Marcello Tonelli, Christoph Wanner
DESCRIPTION: The Kidney Disease: Improving Global Outcomes (KDIGO) organization developed a clinical practice guideline in 2013 on lipid management and treatment of all adults and children with chronic kidney disease (CKD). All forms of CKD are included (non-dialysis-dependent, dialysis-dependent, and kidney transplant recipients). METHODS: The KDIGO Lipid Guideline Development Work Group defined the scope of the guideline, gathered evidence, determined topics for systematic review, and graded the quality of evidence that had been summarized by an evidence review team...
February 4, 2014: Annals of Internal Medicine
https://www.readbyqxmd.com/read/25493951/peritoneal-dialysis-per-se-is-a-risk-factor-for-sclerostin-associated-adynamic-bone-disease
#17
COMPARATIVE STUDY
Rodrigo A de Oliveira, Fellype C Barreto, Monique Mendes, Luciene M dos Reis, João Henrique Castro, Zita Maria L Britto, Igor D B Marques, Aluizio B Carvalho, Rosa M Moysés, Vanda Jorgetti
Chronic kidney disease--mineral bone disorder (CKD-MBD) is a complex syndrome influenced by various factors, such as age, CKD etiology, uremic toxins, and dialysis modality. Although extensively studied in hemodialysis (HD) patients, only a few studies exist for peritoneal dialysis (PD) patients. Since most of these older studies contain no bone biopsy data, we studied the pattern of renal osteodystrophy in 41 prevalent PD patients. The most common presentation was adynamic bone disease (49%). There was a significant inverse association between serum sclerostin (a Wnt/β-catenin pathway inhibitor that decreases osteoblast action and bone formation) and the bone formation rate...
May 2015: Kidney International
https://www.readbyqxmd.com/read/18199805/effects-of-sevelamer-hydrochloride-and-calcium-carbonate-on-renal-osteodystrophy-in-hemodialysis-patients
#18
RANDOMIZED CONTROLLED TRIAL
Aníbal Ferreira, João Miguel Frazão, Marie-Claude Monier-Faugere, Célia Gil, José Galvao, Carlos Oliveira, Jorge Baldaia, Ilidio Rodrigues, Carla Santos, Silvia Ribeiro, Regula Mueller Hoenger, Ajay Duggal, Hartmut H Malluche
Disturbances in mineral metabolism play a central role in the development of renal bone disease. In a 54-wk, randomized, open-label study, 119 hemodialysis patients were enrolled to compare the effects of sevelamer hydrochloride and calcium carbonate on bone. Biopsy-proven adynamic bone disease was the most frequent bone abnormality at baseline (59%). Serum phosphorus, calcium, and intact parathyroid hormone were well controlled in both groups, although calcium was consistently lower and intact parathyroid hormone higher among patients who were randomly assigned to sevelamer...
February 2008: Journal of the American Society of Nephrology: JASN
https://www.readbyqxmd.com/read/23684755/sevelamer-versus-calcium-carbonate-in-incident-hemodialysis-patients-results-of-an-open-label-24-month-randomized-clinical-trial
#19
RANDOMIZED CONTROLLED TRIAL
Biagio Di Iorio, Donald Molony, Cynthia Bell, Emanuele Cucciniello, Vincenzo Bellizzi, Domenico Russo, Antonio Bellasi
BACKGROUND: Whether the use of sevelamer rather than a calcium-containing phosphate binder improves cardiovascular (CV) survival in patients receiving dialysis remains to be elucidated. STUDY DESIGN: Open-label randomized controlled trial with parallel groups. SETTINGS & PARTICIPANTS: 466 incident hemodialysis patients recruited from 18 centers in Italy. INTERVENTION: Study participants were randomly assigned in a 1:1 fashion to receive either sevelamer or a calcium-containing phosphate binder (although not required by the protocol, all patients in this group received calcium carbonate) for 24 months...
October 2013: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/23363879/oral-sodium-thiosulfate-as-maintenance-therapy-for-calcific-uremic-arteriolopathy-a-case-series
#20
Meteb M AlBugami, Jo-Anne Wilson, James R Clarke, Steven D Soroka
BACKGROUND: Calcific uremic arteriolopathy (CUA) is a rare but serious disorder affecting 4% of dialysis patients. Intravenous sodium thiosulfate (IV STS) has been shown as an effective treatment. In Canada, the average cost of IV STS is about CAD 12,000 per month, while the cost of compounded oral STS is CAD 45 per month. METHODS: Prospective cohort where all patients diagnosed with CUA during the year 2011 were included. They were treated initially with IV STS...
2013: American Journal of Nephrology
label_collection
label_collection
2661
1
2
2014-12-10 23:36:45
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"